Pulmatrix Inc (PULM) Stock Price, Quote & News

Company Profile

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical tri...

Industry: Biotechnology

Sector: Healthcare

Phone: 888 355 4440

Website: www.pulmatrix.com

Address:

945 Concord Street, Suite 1217, Framingham, United States

MinnieSteve3 Apr. 24 at 8:52 PM

$PULM From 3/31 to 4/15, short interest increased from 8,053 shares to 19,602 shares. (Previously short interest was 2,505 shares on 3/13.) Games, games, games.

1 · Reply

Nakom Apr. 24 at 2:14 PM

$PULM Hold onto your stock. I for see the dividend being a minimum of $37.50 a share.

2 · Reply

Nakom Apr. 24 at 1:52 PM

$PULM Shares are really drying up. Picked up 8 shares. I refuse to chase it because it will take huge jumps.

0 · Reply

Nakom Apr. 23 at 8:06 PM

$PULM Zero movement on stock. Very good sign. Anticipating a S4 document to come out next week. All good. 👍

0 · Reply

Nakom Apr. 23 at 12:30 PM

$PULM gettyup!!!

0 · Reply

HomeRunHitterXXXXX Apr. 22 at 7:39 PM

$PULM cifr trying to catch us

0 · Reply

hiTHit Apr. 22 at 6:37 PM

$PULM We were so happy six years ago. Back then, none of us were PULM shareholders, and we didn’t know each other.🤓

0 · Reply

Nakom Apr. 22 at 3:58 PM

$PULM Picked up another 80 shares today at $1.42. Listen to an interview with J&J. My gut tells me PUR1800 might be in play again.

1 · Reply

Synchronization Apr. 22 at 1:49 PM

$PULM Private Placement was done at $2.20, no reason to be trading under that

0 · Reply

HomeRunHitterXXXXX Apr. 22 at 3:29 AM

$PULM where?

0 · Reply

Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger

Mar 26, 2026, 8:00 AM EDT - 4 weeks ago

Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

Mar 2, 2026, 8:00 AM EST - 7 weeks ago

Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities

Feb 26, 2026, 8:05 AM EST - 2 months ago

Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results

Dec 18, 2025, 8:05 AM EST - 4 months ago

Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives

Oct 16, 2025, 8:05 AM EDT - 6 months ago

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

Aug 6, 2025, 8:05 AM EDT - 9 months ago

Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

May 15, 2025, 8:05 AM EDT - 1 year ago

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

May 9, 2025, 4:00 PM EDT - 1 year ago

PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

Mar 21, 2025, 8:05 AM EDT - 1 year ago

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

Nov 15, 2024, 8:00 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

GRDX

Nov 13, 2024, 9:00 AM EST - 1 year ago

Pulmatrix and Cullgen Announce Proposed Merger

Nov 13, 2024, 6:00 AM EST - 1 year ago

Pulmatrix Transcript: M&A Announcement

Nov 8, 2024, 10:26 AM EST - 1 year ago

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 9:05 AM EDT - 1 year ago

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

May 29, 2024, 8:45 AM EDT - 2 years ago

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

MNKD

May 15, 2024, 9:35 AM EDT - 2 years ago

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)

May 10, 2024, 8:05 AM EDT - 2 years ago

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

Mar 28, 2024, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

Jan 8, 2024, 9:00 AM EST - 2 years ago

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

Nov 9, 2023, 9:05 AM EST - 2 years ago

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Sep 19, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

Aug 23, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Aug 10, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 11, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Jun 15, 2023, 9:20 AM EDT - 3 years ago

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

May 24, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

May 12, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 2, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Supports World Asthma Day 2023

Mar 30, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

Feb 6, 2023, 9:10 AM EST - 3 years ago

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Jan 25, 2023, 9:05 AM EST - 3 years ago

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"

Jan 23, 2023, 9:05 AM EST - 3 years ago

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology

Jan 4, 2023, 9:05 AM EST - 3 years ago

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Nov 10, 2022, 9:05 AM EST - 3 years ago

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Sep 26, 2022, 9:00 AM EDT - 3 years ago

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

Aug 8, 2022, 9:05 AM EDT - 4 years ago

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Jul 12, 2022, 9:00 AM EDT - 4 years ago

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

May 12, 2022, 9:05 AM EDT - 4 years ago

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

Mar 29, 2022, 9:05 AM EDT - 4 years ago

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

Mar 21, 2022, 12:45 PM EDT - 4 years ago

Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results

Mar 21, 2022, 8:05 AM EDT - 4 years ago

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

Mar 17, 2022, 4:05 PM EDT - 4 years ago

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

Mar 1, 2022, 9:00 AM EST - 4 years ago

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

Feb 24, 2022, 4:05 PM EST - 4 years ago

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split

Feb 1, 2022, 9:00 AM EST - 4 years ago

Pulmatrix Issues Letter to Stockholders

Dec 17, 2021, 4:30 PM EST - 4 years ago

Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering

MinnieSteve3 Apr. 24 at 8:52 PM

$PULM From 3/31 to 4/15, short interest increased from 8,053 shares to 19,602 shares. (Previously short interest was 2,505 shares on 3/13.) Games, games, games.

1 · Reply

Nakom Apr. 24 at 2:14 PM

$PULM Hold onto your stock. I for see the dividend being a minimum of $37.50 a share.

2 · Reply

Nakom Apr. 24 at 1:52 PM

$PULM Shares are really drying up. Picked up 8 shares. I refuse to chase it because it will take huge jumps.

0 · Reply

Nakom Apr. 23 at 8:06 PM

$PULM Zero movement on stock. Very good sign. Anticipating a S4 document to come out next week. All good. 👍

0 · Reply

Nakom Apr. 23 at 12:30 PM

$PULM gettyup!!!

0 · Reply

HomeRunHitterXXXXX Apr. 22 at 7:39 PM

$PULM cifr trying to catch us

0 · Reply

hiTHit Apr. 22 at 6:37 PM

$PULM We were so happy six years ago. Back then, none of us were PULM shareholders, and we didn’t know each other.🤓

0 · Reply

Nakom Apr. 22 at 3:58 PM

$PULM Picked up another 80 shares today at $1.42. Listen to an interview with J&J. My gut tells me PUR1800 might be in play again.

1 · Reply

Synchronization Apr. 22 at 1:49 PM

$PULM Private Placement was done at $2.20, no reason to be trading under that

0 · Reply

HomeRunHitterXXXXX Apr. 22 at 3:29 AM

$PULM where?

0 · Reply

HomeRunHitterXXXXX Apr. 21 at 7:26 PM

$PULM 171000 shares traded and this couldn’t even move 20 cents

1 · Reply

Nakom Apr. 21 at 5:19 PM

$PULM Picked up another 100 shares today. $2.20 is the new floor. No brainer at these price.

1 · Reply

Nakom Apr. 21 at 12:58 PM

$PULM $2.20 incoming. Check out 8k

0 · Reply

HomeRunHitterXXXXX Apr. 21 at 12:33 PM

$PULM

1 · Reply

Nakom Apr. 20 at 4:46 PM

$PULM JMO - but if your looking 👀 for a whole lot of cheap shares I don’t thing they are out there.

0 · Reply

Gugger Apr. 20 at 3:16 PM

$PULM Volume picking up, starts to move ... don't complain next week it moved toooo fast 😉

2 · Reply

Nakom Apr. 20 at 12:43 PM

$PULM A lot of M/A this year. Good time to have assets for sale. Someone will pay!!!💰

0 · Reply

HomeRunHitterXXXXX Apr. 17 at 8:08 PM

$PULM 67k shares traded and it didn’t move

0 · Reply

Nakom Apr. 17 at 6:54 PM

$PULM Maybe an S-4 form filed over the weekend. All good. Have a great weekend fellow longs.

0 · Reply

Mzahir80 Apr. 17 at 5:52 PM

$PULM oh wow!!! What happened here??? Where is Gaga?

1 · Reply

thezsmith Apr. 17 at 12:54 PM

$SPY hey guys the "ships can go through for the rest of the ceasefire" news is comical.... the ceasefire is set to end in a few days 🤣 how many shops are fitting through in that amount of time. Every day im amazed by theblack of critical thinkkng skills everywhere, i will be adding to my $UAL short and $PULM if they pump. Thank you for your attention to this matter.

3 · Reply

Nakom Apr. 16 at 1:54 PM

$PULM Not that many shares to be had today. Not surprised about that. With the form D being filed yesterday people are in a wait and see mode. Good news is reverse merger is coming along just fine. We all know though the real money is in the sale of the assets.

1 · Reply

Market Cap	5.11M
Revenue (ttm)	0.00
Net Income (ttm)	-5.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	5,600
Avg Vol	59,196
Day's Range	N/A - N/A
Shares Out	3.65M
Stochastic %K	58%
Beta	1.97
Analysts	Strong Buy
Price Target	$10.00